A case of breast cancer: Suppression of lactation-related FDG uptake 2 days after cabergoline administration

Hiroyuki Kuroda; Takeshi Yoshizako; Nobuko Yamamoto; Yuko Kataoka; Miki Hyakudomi; Masayuki Itakura; Yasushi Kaji

doi:10.1177/20584601231174611

A case of breast cancer: Suppression of lactation-related FDG uptake 2 days after cabergoline administration

Acta Radiol Open. 2023 May 4;12(5):20584601231174611. doi: 10.1177/20584601231174611. eCollection 2023 May.

Authors

Hiroyuki Kuroda¹, Takeshi Yoshizako¹, Nobuko Yamamoto¹, Yuko Kataoka², Miki Hyakudomi³, Masayuki Itakura⁴, Yasushi Kaji¹

Affiliations

¹ Department of Radiology, Shimane University Faculty of Medicine, Izumo, Japan.
² Pathology Division, Faculty of Medicine Shimane University, Izumo, Japan.
³ Hyakudomi Clinic, Japan.
⁴ Department of Digestive & General Surgery, Shimane University Faculty of Medicine, Izumo, Japan.

Abstract

We present a case of a 35-year-old woman with breast cancer in lactation 3 months after childbirth, in which a lactation inhibitor was useful for 18F-FDG PET/CT examination. Via ultrasonography and biopsy with histopathology, we diagnosed the lesion in the upper region of the left breast as invasive ductal carcinoma. She stopped breastfeeding and was administered cabergoline to suppress lactation. Two days after the administration, 18F-FDG PET/CT revealed segmental uptake (10 cm in diameter) and no lactation-related uptakes. Dynamic MRI also revealed a segmental enhancement of the same size as 18F-FDG PET/CT. The lactation inhibitor was useful to delineate the extent of the lesion during the 18F-FDG PET/CT examination.

Keywords: PET/CT; breast cancer; cabergoline; dopamine receptor agonist; fluorodeoxyglucose; lactation.

Publication types

Case Reports